Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer

Lade...
Vorschaubild
Dateien
Dannull_221637.pdf
Dannull_221637.pdfGröße: 431.21 KBDownloads: 171
Datum
2000
Autor:innen
Dannull, Jens
Diener, Pierre-André
Prikler, Ladislav
Fürstenberger, Gregor
Cerny, Thomas
Schmid, Ulrico
Ackermann, Daniel K.
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
ArXiv-ID
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Open Access Green
Sammlungen
Core Facility der Universität Konstanz
Gesperrt bis
Titel in einer weiteren Sprache
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Zusammenfassung

Immunotherapy of prostate cancer (CaP) may be a promising novel treatment option for the management of advanced CaP. However, the lack of suitable tumor antigens remains a major obstacle for the rational design of vaccines. To characterize potential CaP antigens, we determined the mRNA expression of the prostate-specific genes C1, C2, C5, PAGE-1, and prostate stem cell antigen (PSCA) in hormone-refractory CaP, benign prostatic hyperplasia, CaP cell lines, and CaP specimens. Among these gene products, only expression of PSCA appears to be retained in the majority of advanced CaP samples, as shown by reverse transcription-PCR analyses. Peptide fragments of PSCA presented in the context of major histocompatibility molecules could serve as recognition targets for CD8 T cells, provided these lymphocytes were not clonally deleted or peripherally tolerized. Our goal was to determine whether the human T-cell repertoire could recognize PSCA-derived peptide epitopes in the context of a common class I allele, HLA-A0201. Of nine peptides that, according to HLA-A0201 binding motifs, were candidate ligands of A0201 class I molecules, three peptides were able to stabilize HLA-A0201 molecules on the cell surface. One of the latter peptides, encompassing amino acid residues 14-22, was capable of generating a PSCA-specific T-cell response in a human lymphocyte culture from a patient with metastatic CaP. PSCA-specific CTLs recognized peptide-pulsed targets as well as three prostate carcinoma lines in cytotoxicity assays, indicating that this peptide could be endogenously processed. In conclusion, our findings establish PSCA as a potential target for antigen-specific, T cell-based immunotherapy of prostate carcinoma.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690DANNULL, Jens, Pierre-André DIENER, Ladislav PRIKLER, Gregor FÜRSTENBERGER, Thomas CERNY, Ulrico SCHMID, Daniel K. ACKERMANN, Marcus GRÖTTRUP, 2000. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. In: Cancer Research. 2000, 60(19), pp. 5522-5528. ISSN 0008-5472. eISSN 1538-7445
BibTex
@article{Dannull2000Prost-22163,
  year={2000},
  title={Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer},
  url={http://cancerres.aacrjournals.org/content/60/19/5522},
  number={19},
  volume={60},
  issn={0008-5472},
  journal={Cancer Research},
  pages={5522--5528},
  author={Dannull, Jens and Diener, Pierre-André and Prikler, Ladislav and Fürstenberger, Gregor and Cerny, Thomas and Schmid, Ulrico and Ackermann, Daniel K. and Gröttrup, Marcus}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/22163">
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Prikler, Ladislav</dc:creator>
    <dc:creator>Cerny, Thomas</dc:creator>
    <dc:creator>Schmid, Ulrico</dc:creator>
    <dc:contributor>Dannull, Jens</dc:contributor>
    <dc:rights>terms-of-use</dc:rights>
    <dc:contributor>Schmid, Ulrico</dc:contributor>
    <dc:creator>Dannull, Jens</dc:creator>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/22163/2/Dannull_221637.pdf"/>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/22163"/>
    <dc:creator>Diener, Pierre-André</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-27T08:47:39Z</dc:date>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:issued>2000</dcterms:issued>
    <dc:language>eng</dc:language>
    <dc:contributor>Prikler, Ladislav</dc:contributor>
    <dc:contributor>Cerny, Thomas</dc:contributor>
    <dc:contributor>Gröttrup, Marcus</dc:contributor>
    <dc:creator>Fürstenberger, Gregor</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:contributor>Diener, Pierre-André</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-27T08:47:39Z</dcterms:available>
    <dc:contributor>Ackermann, Daniel K.</dc:contributor>
    <dc:contributor>Fürstenberger, Gregor</dc:contributor>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/22163/2/Dannull_221637.pdf"/>
    <dcterms:title>Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer</dcterms:title>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:abstract xml:lang="eng">Immunotherapy of prostate cancer (CaP) may be a promising novel treatment option for the management of advanced CaP. However, the lack of suitable tumor antigens remains a major obstacle for the rational design of vaccines. To characterize potential CaP antigens, we determined the mRNA expression of the prostate-specific genes C1, C2, C5, PAGE-1, and prostate stem cell antigen (PSCA) in hormone-refractory CaP, benign prostatic hyperplasia, CaP cell lines, and CaP specimens. Among these gene products, only expression of PSCA appears to be retained in the majority of advanced CaP samples, as shown by reverse transcription-PCR analyses. Peptide fragments of PSCA presented in the context of major histocompatibility molecules could serve as recognition targets for CD8 T cells, provided these lymphocytes were not clonally deleted or peripherally tolerized. Our goal was to determine whether the human T-cell repertoire could recognize PSCA-derived peptide epitopes in the context of a common class I allele, HLA-A0201. Of nine peptides that, according to HLA-A0201 binding motifs, were candidate ligands of A0201 class I molecules, three peptides were able to stabilize HLA-A0201 molecules on the cell surface. One of the latter peptides, encompassing amino acid residues 14-22, was capable of generating a PSCA-specific T-cell response in a human lymphocyte culture from a patient with metastatic CaP. PSCA-specific CTLs recognized peptide-pulsed targets as well as three prostate carcinoma lines in cytotoxicity assays, indicating that this peptide could be endogenously processed. In conclusion, our findings establish PSCA as a potential target for antigen-specific, T cell-based immunotherapy of prostate carcinoma.</dcterms:abstract>
    <dc:creator>Ackermann, Daniel K.</dc:creator>
    <dc:creator>Gröttrup, Marcus</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:bibliographicCitation>Cancer Research ; 60 (2000), 19. - S. 5522-5528</dcterms:bibliographicCitation>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
Prüfdatum der URL
2017-12-21
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Diese Publikation teilen